Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.58 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959258 | 0.83 | ALDH1A1 (0.57) | ALDH1A1MAPTCYP2C9THRBMEN1 | |
| Hydrochloric Acid SCHEMBL5500274 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPTCYP2C9THRBMEN1 | |
| SCHEMBL14161697 | 0.81 | GRIN2B (0.76) | GAAALDH1A1MAPTL3MBTL1MBTD1 | |
| SCHEMBL13648726 | 0.78 | L3MBTL3 (0.72) | GAAALDH1A1MAPTL3MBTL1MBTD1 | |
| SCHEMBL13648728 | 0.78 | L3MBTL3 (0.72) | GAAALDH1A1MAPTL3MBTL1MBTD1 | |
| SCHEMBL13200798 | 0.77 | GRIN2B (0.70) | GAAALDH1A1MAPTL3MBTL1MBTD1 | |
| SCHEMBL861784 | 0.77 | GRIN2B (0.65) | GAAALDH1A1MAPTL3MBTL1MBTD1 | |
| SCHEMBL372411 | 0.77 | GRIN2B (0.65) | GAAALDH1A1MAPTL3MBTL1MBTD1 | |
| SCHEMBL372412 | 0.77 | GRIN2B (0.65) | GAAALDH1A1MAPTL3MBTL1MBTD1 | |
| SCHEMBL22848097 | 0.76 | L3MBTL3 (0.70) | GAAALDH1A1MAPTL3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| CN-101326166-A | Novel N-sulfamoyl-piperidine amides for the prevention or treatment of obesity and related disorders | SOLVAY PHARM GMBH (DE) | 2008-12-17 | — | — | CN | disclosed |
| EP-1960359-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| WO-2007065948-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065948-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | FABP4, GPR119, SRM | GAA 171/4885ALDH1A1 200/4885MAPT 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.